Liquid chromatography-high resolution mass spectrometry for broad-spectrum drug screening of dried blood spot as microsampling procedure. by Joye, T. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Liquid chromatography-high resolution mass spectrometry for
broad-spectrum drug screening of dried blood spot as microsampling
procedure
Authors: Joye T, Sidibe´ J, De´glon J, Karmime A, Sporkert F, Widmer C,
Favrat B, Lescuyer P, Augsburger M, Thomas A
Journal: Analytica Chimica Acta
Year: 2019
Issue: 1063
Pages: 110-116
DOI: 10.1016/j.aca.2019.02.011
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Accepted Manuscript
Liquid Chromatography –High Resolution MS-based assay for broad-spectrum drug
screening of dried blood spot as microsampling procedure
Timothée Joye, Jonathan Sidibe, Julien Déglon, Abderrahim Karmime, Frank
Sporkert, Christèle Widmer, Bernard Favrat, Pierre Lescuyer, Marc Augsburger,
Aurélien Thomas
PII: S0003-2670(19)30185-0
DOI: https://doi.org/10.1016/j.aca.2019.02.011
Reference: ACA 236575
To appear in: Analytica Chimica Acta
Received Date: 22 November 2018
Revised Date: 28 January 2019
Accepted Date: 4 February 2019
Please cite this article as: T. Joye, J. Sidibe, J. Déglon, A. Karmime, F. Sporkert, C. Widmer, B. Favrat,
P. Lescuyer, M. Augsburger, A. Thomas, Liquid Chromatography –High Resolution MS-based assay
for broad-spectrum drug screening of dried blood spot as microsampling procedure, Analytica Chimica
Acta, https://doi.org/10.1016/j.aca.2019.02.011.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
1 
Liquid Chromatography –High Resolution MS-based assay for broad-spectrum drug screening of dried blood spot as 1 
microsampling procedure 2 
3 
Timothée Joye1,  Jonathan Sidibe1,  Julien Déglon1,  Abderrahim Karmime 2,  Frank 4 
Sporkert1,  Christèle Widmer1,  Bernard Favrat3,  Pierre Lescuyer2,  Marc Augsburger1,  5 
Aurélien Thomas1  6 
1 Forensic Toxicology and chemistry unit, University centre of legal medicine, Lausanne-Geneva, Switzerland 7 
2 Division of Laboratory Medicine, University Hospitals of Geneva, Switzerland 8 
3 Unit of medicine and traffic psychology, University centre of legal medicine, Lausanne-Geneva, Switzerland 9 
10 
Corresponding author: 11 
Prof. Aurelien Thomas 12 
Unit of Toxicology, CURML  13 
Vulliette 04 street, 14 
1000 Lausanne 25 | Switzerland 15 
Telephone: +41213143744 16 
Fax: +41213147329 17 
Aurelien.Thomas@chuv.ch 18 
19 
Nonstandard abbreviations: STA, systematic toxicological analysis; GUS, general unknown screening; LC, 20 
liquid chromatography; HRMS, high resolution mass spectrometry; DDA, data-dependent acquisition; DBS, 21 
dried blood spot; DMS, dried matrix spot; MRM, multiple reaction monitoring; LOI, limit of identification; 22 
LOD, limit of detection; DIA, data-independent acquisition; SWATH, sequential window acquisition of all 23 
theoretical fragment-ion spectra; MSX, multiplexed. 24 
ACCEPTED MANUSCRIPT
2 
Abstract 25 
Background: Hyphenation of liquid chromatography (LC) with high-resolution mass spectrometry (HRMS) 26 
offers the potential to develop broad-spectrum screening procedures from low volumes of biological matrices. In 27 
parallel, dried blood spot (DBS) has become a valuable tool in the bioanalysis landscape to overcome 28 
conventional blood collection issues. Herein, we demonstrated the applicability of DBS as micro-sampling 29 
procedure for broad-spectrum toxicological screening.  30 
Methods: A method was developed on a HRMS system in data dependant acquisition (DDA) mode using an 31 
extensive inclusion list to promote collection of relevant data. 104 real toxicology cases were analysed, and the 32 
results were cross-validated with one published and one commercial screening procedures. Quantitative MRM 33 
analyses on a triple quadrupole instrument were also performed on identified substances as a complementary 34 
confirmation procedure. 35 
Results: The method showed limits of identification (LOIs) in appropriateness with therapeutic ranges for all the 36 
classes of interest. Applying the three screening approaches on 104 real cases, 271 identifications were 37 
performed including 14 and 6 classes of prescribed and illicit drugs, respectively. Among the detected 38 
substances, 23% were only detected by the proposed method. Based on confirmatory analyses, we demonstrated 39 
that the use of blood micro-samples did not impair the sensitivity allowing more identifications in the low 40 
concentration ranges. 41 
Conclusion: A LC-HRMS assay was successfully developed for toxicological screening of blood microsamples 42 
demonstrating a high identification power at low concentration ranges. The validation procedure and the analysis 43 
of real cases demonstrated the potential of this assay by supplementing screening approaches of reference. 44 
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1. Introduction45 
Systematic toxicological analysis (STA) is of primary importance in both clinical and forensic toxicology. It 46 
generally consists of a combination of analytical strategies including immunoassays, and chromatography 47 
hyphenated to mass spectrometry [1-3]. In STA, orientation tests and preliminary screening are performed, 48 
which can be referred as general unknown screening (GUS)[4]. The goal of this procedure is to conclude in a 49 
precise and unambiguous way if any substance of toxicological interest has been consumed or not prior 50 
confirmatory quantitative analysis[5, 6]. This challenging task depends on the biological matrix, sample 51 
preparation, analytical technique, and the compound database. 52 
Currently, liquid chromatography (LC) hyphenated with mass-spectrometry (MS) is partially replacing gas 53 
chromatography (GC)-MS approaches regarding GUS in blood and urine and numerous applications have been 54 
mentioned[6, 7]. 55 
The introduction of high-resolution MS (HRMS) analyser and especially Orbitrap technology, gives the 56 
opportunity to investigate several analytical strategies including full scan data dependent acquisition (DDA) [8-57 
10]. The latest generation of Fourier transform MS, routinely reaches mass resolution above 70,000 at 1-ppm 58 
mass accuracy and high spectral resolution capacities. Continual improvement of scan rate frequencies and 59 
dynamic range lead to instruments particularly adapted for large-scale comprehensive screening in complex 60 
matrices [11-13]. The increased mass accuracy allows to facilitate identification by reducing the number of 61 
possible chemical formulas [6]. Lastly, this technology offers fast positive/negative polarity switching at high 62 
scan rates allowing the simultaneous analysis of a wide range of substances [14]. Therefore, HR full-scan 63 
methods are very suitable for the development of large-scale screening procedure and especially for drug 64 
screening [3, 15]. By improving the mass resolution power, HRMS increases the selectivity, therefore reducing 65 
the potential interferences [10]. The associated improvement in terms of sensitivity could allow to reduce the 66 
volume of biological matrices used for the screening procedure.  67 
Currently, urine is the gold standard regarding screening approaches since its sampling is simple and non-68 
invasive. Moreover, urine is relatively poor in proteins and lipids that could interfere with the signal of the 69 
analytes and concentrate most analytes reducing potential sensitivity issues [16]. Compared to urine, blood 70 
sampling presents significant advantages since it is difficult to counterfeit, and the toxicological interpretation of 71 
concentration is facilitated making it the gold standard for confirmatory analysis [17]. However, blood sampling 72 
induces several logistical and analytical issues. Indeed, classical venepuncture is invasive, requires special 73 
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logistic and medical supervision [18]. In addition, in some situations, especially concerning problematic and 74 
vulnerable patient population, only limited volumes of blood are available [19]. To bypass those issues, the use 75 
of cellulose paper cards has been mentioned [20]. The first use of dried blood spot (DBS) has been reported by 76 
Guthrie and Susie more than 50 years ago, for paediatric purpose [21]. Among advantages, DBS sampling 77 
requires the collection of a small volume of blood (5-10 µL). Moreover, it is performed by finger or heel 78 
pricking that can be performed by a technician or by the patient himself after minimal training in a non-hospital 79 
environment [22]. The adsorption and drying of blood on a solid phase makes analytes less reactive, leading to 80 
facilitated shipment and storage and reducing the costs [23]. Lastly, during blood adsorption and drying most 81 
pathogenic agents are deactivated leading to a safer handling of samples [24].  82 
Various applications of detection of drugs using dried matrix spots (DMS) [14, 27] and especially DBS sampling 83 
have already been presented [7, 23, 28, 29]. For instance, analyses on DBS have been used for both quantitative 84 
(quantification of benzodiazepines) [22] and screening approaches either for doping screening [7] or for 85 
toxicological analyses using a targeted strategy [30]. Indeed, DBS presents several advantages for MS-based 86 
analyses since samples preparation can be accelerated and facilitated. Moreover, using organic solvents, lipids 87 
and proteins are mostly being retained on the paper-card allowing the reduction of matrix effects, making this 88 
sampling support particularly adapted to MS-based strategies [22, 31-33]. We previously demonstrated the 89 
potential of DBS for  targeted drug screening using a multiple reaction monitoring (MRM)-DDA approach [30]. 90 
In the present study, we extend the screening capabilities from DBS samples using the analytical advantages 91 
brought by the HRMS, notably by broadening the number of possible identifications. In this way, a full-scan-92 
DDA LC-HRMS method was developed using an inclusion list of more than 1000 compounds including all 93 
classes of interest. The developed assay requires limited sample preparation and allows the identification of a 94 
wide-range of compounds. Representative substances were tested for the chromatographic and MS parameters 95 
optimisation including non-exhaustively amphetamines, benzodiazepines, cocaine, antidepressants, neuroleptics, 96 
opioids, NPS, anticonvulsants, and THC-COOH. In a second time, a subset of 30 substances was used for the 97 
determination of the limits of identification (LOIs). This method was then assessed using 104 behavioural 98 
toxicology real cases. The results were cross-validated by two published screening methods used in routine [30, 99 
34]. Confirmation assessment were also performed using quantitative analysis as a complementary approach to 100 
evaluate the efficiency of the developed routine screening method presented herein. 101 
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2. Methods 102 
2.1 Standards and reagents 103 
Water, methanol, formic acid (FA), dichloromethane, hydrochloric acid, hexane and ethyl acetate UPLC, 104 
potassium and sodium chloride, boric acid, and ammonium formate were purchased from Biosolve, Sigma-105 
Aldrich or Merck. Drug standards were purchased at 1 mg/ml either from Cerilliant or Lipomed. Blank, 106 
lyophilized whole blood for method development was purchased from ACQ Science. Protein saver cards for 107 
DBS sampling were purchased from Whatman. Whole blood external quality control (EQC) PM100 for pain 108 
management and drug of abuse (DoA-I VB low) were purchased from UTAK® (Supplemental Table 1) and 109 
Medidrug® (Supplemental Table 2) respectively. 110 
2.2 Sample preparation 111 
For method development, blank whole blood was spiked with drugs at different concentrations (1, 5, 10, 20 and 112 
50 ng mL-1). Methanolic standard were evaporated under a nitrogen flow at room temperature before 113 
reconstitution in blood. Then 10 µL were deposited on a DBS filter paper card. Drugs were tested for limits of 114 
identification and detection determination, chromatography and identification optimisation including 115 
benzodiazepines, NPS, neuroleptics, opioids, antidepressants, synthetic cannabinoids, amphetamines, 116 
anticonvulsant, cocaine and cannabinoids. A double extraction process on DBS was developed. One spot was 117 
extracted using 100 µL of methanol and mixed for 2 minutes. A second spot was extracted using 100 µL of 118 
borate buffer 0.5 M pH 9.5, after mixing for 2 minutes, 300 µL of DCM: Hexane: Ethyl Acetate (5:4:1) were 119 
added. This second spot was then centrifugated and the organic phase was mixed with the 100 µL of methanol 120 
extract from the first extraction in a new tube. Organic solvents were then evaporated at room temperature using 121 
a nitrogen flow, and samples were reconstituted with 50 µL of water. 122 
 2.3 LC-HRMS method 123 
All samples were injected (10 µL injection volume) using partial loop injection mode on the LC-Q Exactive Plus 124 
system (Thermo Scientific, Bremen, Germany). Chromatographic separation using a Thermo Scientific Ultimate 125 
3000 LC system with a Phenomenex 2.6 µm C18 (2.1 X 50 mm) maintained at 45°C. Mobile phase A consisted 126 
of ammonium formate 10 mM pH 3.3 and mobile phase B of MeOH with 0.1 % FA. Phase B was ramped 127 
linearly from 2 to 98% over 6 minutes. The column was washed at 98 % of B for 3 minutes, followed by a 3.5 128 
minutes reequilibration at 2 % of B. The LC was coupled to the MS via a heated ESI source associated with a Q 129 
Exactive Plus operating in full-scan DDMS2 positive polarity with a Tsim DDMS2 negative polarity switching 130 
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between min 6 and 7 only for the specific detection of THC-COOH (supplemental Figure 1A). The ionisation 131 
spray voltage was set to 3 kV, sheath gas flowrate was set to 40 and auxiliary gas flowrate to 10 (both in 132 
arbitrary unit). HCD fragmentation was performed with an inclusion list containing 1008 compounds using NCE 133 
at 70 eV in positive polarity and 30 eV in negative polarity. No dynamic exclusion was set. Resolution was set to 134 
70’000 for the full scan experiment in positive polarity while it was set to 17’500 during the polarity switching 135 
and the fragmentation experiments. 136 
2.3 Data analysis  137 
Data analysis was performed using TraceFinder (Thermo Scientific) and a database containing more than 1000 138 
compounds (Supplemental Table 3). Four criteria were used for substance identification including the mass over 139 
charge ration (m/z), the isotopic pattern (IP), the retention time (RT) and the library search (LS) based on the 140 
fragmentation spectra comparison. Peak detection was based on a S/N threshold of 10 with a 10 ppm tolerance. 141 
Library search was considered successful with a match greater or equal to 50 %. IP needed to fit over 65% 142 
allowing 10 ppm mass and 20% intensity deviations and RT was considered with a 30 seconds precision. 143 
Substances identification was still possible if either the RT or the LS do not match.. 144 
2.4 Method evaluation  145 
LOIs were measured using a list of 30 substances including most classes of interest (Table 1). LOIs were 146 
evaluated by injecting 5 spiked replicates at 1, 5, 10 and 20 ng mL-1. To minimise the risk of false negative and 147 
as described elsewhere, LOI was considered as the lowest concentration at which the substances are detected and 148 
identified in all five replicates based on the four criteria previously described [35, 36]. Limits of detection 149 
(LODs) were defined as the minimal concentration at which at least the accurate mass precursor ion is detectable 150 
[14]. Method reproducibility and instrument response were then evaluated using whole blood controls EQC 151 
UTAK® pain management PM 100 (Supplemental Table 1) and the lowest concentration Medidrug® for drug of 152 
abuse (Supplemental Table 2) spotted on a filter paper card. Each QC was injected at the beginning and the end 153 
of each sequence. A QC was considered acceptable when all its substances targeted by the method were 154 
identified regarding the four criteria. Selectivity was assessed by injecting ten different blood samples spotted on 155 
DBS. Matrix effect (ME) and recovery (RE) was evaluated according to the approach described by Matuszewski 156 
et al [37], three sample sets were prepared including 30 representative substances (Table 1). Five different blank 157 
blood sample or neat standard were spiked with those substances at two concentration levels (20 and 200 ng mL-158 
1). Sample set 1 represented neat standards. Sample set 2 blank blood matrix spots spiked after extraction while 159 
sample set 3 represented blank blood matrix spiked and spotted before extraction.  160 
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To evaluate and confirm the efficiency of the whole process, 104 samples from forensic and clinical toxicology 161 
were analysed. Those samples were also analysed by two other routine LC-MS methods. The first one was 162 
developed for forensic toxicology using one 10 µL DBS sample. The spot was introduced into a vial with 100 163 
µL of methanol and injected on the LC-MS/MS system. The analysis was performed on a Qtrap® 5500 (AB, 164 
Sciex) working in targeted multiple reaction monitoring (MRM)-DDA. The chromatography was performed both 165 
on a reverse phase (RP) and a Hilic column in parallel [30]. The second one was developed for clinical 166 
toxicology on a Toxtyper LC-IT-MS System (Brucker). Sample preparation was based on alkaline liquid/liquid 167 
extraction with sodium carbonate 1M and butyl acetate from 500 µL of whole blood.  The method was based on 168 
low-resolution ion trap technology after a standard RP chromatographic separation. The MS experiment was 169 
performed in full-scan DDA with continuous positive/negative ionisation mode switching [34]. Identifications 170 
performed by the 3 methods have been compared as a cross-validation step. The detection of a substance was 171 
confirmed either if it was detected by at least two of the assessed methods or if its identification was 172 
unambiguous. Carryover was evaluated by injecting a methanol sample after each analysed blood sample and by 173 
analysing 10 different blank whole blood samples after the injection of the 104 real cases. In addition, sensitivity 174 
assessment and identification confirmation has been processed using quantitative analysis. 175 
3. Results and discussion 176 
3.1 Sample preparation 177 
DBS provides several well-known advantages toward sample collection. Moreover, the use of blood micro-178 
sampling was described as a promising technique to simplify sample preparation prior to the analysis and reduce 179 
the solvent volumes [30, 38]. Using only two 10 µL spots, a limited sample preparation was sufficient to 180 
sensitively detect all the classes of drugs of interest in their therapeutic or legal range. The development of such 181 
micro-sampling strategies presents an alternative for blood collection in non-hospital environment facilitating 182 
potential large cohort studies [25].  In addition, the combination of simplified sampling with large-scale 183 
adaptative screening approaches could be a public health asset for monitoring habits of consumption and for 184 
targeted prevention. For instance, the emergence of quickly evolving novel psychoactive substances (NPS) 185 
emphasize the risk for the population requiring large-scale adaptative analytical strategies [26]. 186 
 187 
The method was validated according to the recommendations regarding qualitative approaches [39, 40]. Water 188 
was selected as reconstitution solvent based on a compromise between specificity for a maximum of compounds 189 
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with different physico-chemical properties and chromatography. Selectivity was investigated using ten blank 190 
blood samples spotted on DBS and ten clean filter paper cards. No effects were observed extracting and 191 
analysing clean paper spots, suggesting that no substances were released from the paper during the extraction 192 
procedure. No interfering compounds impaired the detection of the substances of interest analysing blank DBS 193 
samples. The systematic injection of a blank methanol after every analysed samples did not revealed carry-over 194 
even after injection of the highest EQC level (i.e. no remaining peaks were observed in the injected methanol for 195 
those exact masses). This was confirmed from real cases analyses since no carryover was observed after the 196 
injection of samples containing high concentrations of benzoylecgonine (2900 ng mL-1), tramadol (1400 ng mL-197 
1) or zolpidem (1200 ng mL-1). The RE and ME results for the DBS extraction process are depicted in Table 1. 198 
The mean ME at 20 ng mL-1 was 34 % ranging from -53 % to 319 % and 13 % at 200 ng mL-1 ranging from -42 199 
% to 178 %. RE was ranging from 36 % to 121 % for respectively benzoylecgonine and cocaine at 20 ng mL-1 200 
and from 22 to 71 % for respectively methamphetamine and fluoxetine at 200 ng/ml. Maximal ion suppression 201 
was observed for THC-COOH while maximal ion enhancement was observed for fluoxetine. Those ME and RE 202 
values are in accordance to previous studies [7, 32, 41] 203 
3.2 Detection and identification 204 
Despite several advantages provided by DBS, the use of micro-sampling requires highly sensitive instruments. 205 
LODs and LOIs for the 30 model compounds are listed in Table 1. As described above, LOI was defined as the 206 
lowest concentration where at least 3 of the 4 identification criteria (m/z, IP, RT and LS) were fulfilled while 207 
LOD was based only on the parent peak detection explaining the slight differences between those parameters 208 
[11, 14]. LOIs were determined to be equal or lower than 20 ng mL-1 for all the 30 substances tested including 11 209 
different classes of molecules, which was the initial goal. LOI was measured at 20 ng mL-1 for one substance 210 
(Gabapentin), while 4 substances have been successfully identified in all 5 replicates at 5 and 10 ng mL-1. For 211 
most of the tested substances (63 %) the LOI was assessed to be 1 ng mL-1. Determined LOIs were confirmed by 212 
the identification of all substances in the lowest EQC levels (Supplemental table 1 and 2). LOD and LOI were 213 
found to be in adequation with the therapeutic ranges [42] or the legal thresholds according to the Swiss 214 
legislation [43]. Regarding identification, parameters were selected to maximise the method efficiency and 215 
reduce the potential number of false negatives. Further investigation by the operator is required when either the 216 
library spectra or the retention time does not match. The use of such an approach allows identifications by post-217 
processing after database adjustments. By relaxing those identification criteria, the sensitivity is increased 218 
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leading to a higher risk of false positive identification. Therefore, a careful data handling is performed by the 219 
operator to assess whether it is a true or false positive. 220 
 221 
3.3 Application of the method on real cases 222 
From the three different screening methods, 271 identifications were validated among the 104 clinical and 223 
forensic toxicology blood samples (Supplemental Table 4). In total, six classes of illicit drugs (amphetamines, 224 
cannabinoids, opioids, NPS and LSD) and 14 classes of prescribed drugs including non-exhaustively antifungals, 225 
antimalarials, antidiabetics, antihistaminic, beta-blockers, or proton-pump inhibitors were detected. The 226 
prescribed drugs were summarized as five classes of prescribed drugs (benzodiazepines, neuroleptics, 227 
antidepressants, anaesthetics/analgesics and other drugs) for better representation. In 24 cases, no compound was 228 
detected and identified while in the 80 other cases, a total of 79 different substances were confirmed. The 229 
targeted MRM-DDA approach on DBS allowed the identification of 57 % of the substances while using the 230 
Toxtyper® on whole blood this number has increased to 72 %. Using the HRMS-DDA full-scan approach, 99 % 231 
of the “hits” were identified on DBS confirming the efficiency of the developed method (Figure 1 A). As 232 
expected THC-COOH was the most detected substance being present in more than 46 % of all the cases (104) 233 
(Figure 2). Without considering THC-COOH which is targeted only by the HRMS-DDA approach, the 234 
percentage of identification respectively increases to 87% and 69 % for the Toxtyper and the MRM-DDA. 235 
Cocaine, benzodiazepines and amphetamines were respectively detected in 19 %, 17 % and 8 % of the cases 236 
(Figure 2). A total of 18% of the cases were containing either an anaesthetic or an analgesic including ketamine 237 
or lidocaine. Other drugs were responsible for 13 % of all identifications while one case of NPS (mephedrone) 238 
and one containing LSD were listed. The differences between the percentage of detected substances and the 239 
occurrence in cases (reaching more than 170%) can be explained by the concomitant consumption of 2 or more 240 
drugs (55 % of the positive cases). Cannabinoids (represented only by THC-COOH) were the most single-drug 241 
consumed (80% of the cases positive to only one substance). Quantitative confirmations were performed on 242 
qualitatively identified substances targeted by the 3 methods. As confirmed by the quantitative results, the 243 
number of identifications using HRMS is increased in the lowest concentration ranges (see Figure 1B). As an 244 
illustration, at concentrations between 0 to 10 ng mL-1, 40 % and 50 % of the confirmed substances detected by 245 
the HRMS-DDA procedure were respectively not identified by the MRM-DDA and the Toxtyper approaches. At 246 
the opposite, the 3 methods were able to detect all the compounds of interest from concentrations higher than 247 
200 ng mL-1. The HRMS improvement in terms of selectivity also results in an increase of sensitivity for full-248 
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scan approaches allowing to work with blood micro-samples. Nevertheless, the demonstrated gain of sensitivity 249 
also results in higher risks of false positive. Peak area thresholds have been implemented for well-ionised 250 
substances and classic contaminants such as cocaine or methadone. 251 
Due to the number of substances to cover and the diversity of physico-chemical properties, the development of 252 
an unbiased and sensitive screening procedure is a difficult task 30. Current HRMS technologies offer the 253 
possibility to use either DDA [41] or data independent acquisition (DIA) including sequential window 254 
acquisition of all theoretical fragment-ion spectra (SWATH) [44, 45]  or multiplexed (MSX) [46]. A recent study 255 
demonstrated the interest of SWATH in comparison to conventional DDA for the analysis of coeluting 256 
substances in complex matrices [47]. Despite the theoretical advantages of DIA strategies for toxicological 257 
screening, these approaches generate complex composite MS/MS spectra, which may hinder the identification of 258 
substances in the low concentration ranges. These issues would be overcome with the development of more 259 
efficient search algorithms and deconvolution processes for DIA routine applications [48].   260 
Unlike DIA approaches, a limiting factor of DDA using intensity threshold as the main criteria would be the 261 
cycle time for fragmentation in case of coelution which can lead to prioritize MS/MS acquisitions of matrix 262 
interferences over pertinent compounds [47]. Even if DDA limits retrospective data evaluation because only 263 
know precursors are selected for fragmentation, by producing better fragmentation spectra than DIA [47, 49], the 264 
use of DDA with a large inclusion list (i.e. more than 1000 substances as demonstrated herein) thus allow the 265 
instrument to spend time only on collecting relevant data. Besides, the inclusion list flexibility allows the fast 266 
and easy adaptation to any new substances increasing the method identification power. 267 
4. Conclusion 268 
In summary, a large-scale HRMS toxicology screening strategy was developed on DBS samples.  The method 269 
operating in full-scan DDA using an inclusion list of more than 1000 compounds showed a high identification 270 
power in which new substances can easily be implemented. The method was cross-validated with one published 271 
and one commercial screening procedures. Confirmation quantitative analyses on identified compounds have 272 
demonstrated that despite the use of blood micro-samples the sensitivity was not impaired providing several 273 
advantages.   Regarding the importance of screening procedures within the STA, rapid and comprehensive GUS 274 
tools are necessary and should be proposed. The hyphenation of DBS with HRMS might be an attractive solution 275 
combining a friendly sampling process with highly selective and sensitive MS-based detection.  This method that 276 
was validated [39]  and implemented for its use in routine opens notably new toxicological perspectives towards 277 
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population monitoring in non-hospital environment. In a near future, the development of online shared libraries 278 
such as m/z cloud and bioinformatic tools should allow to broaden the number of efficient large-scale screening 279 
strategies especially regarding non-targeted approaches. 280 
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Tables: 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 
  Substance 
LOI  
(ng mL-1) 
LOD 
 (ng mL-1) 
RE (CV) 
(20  ng mL-1) 
ME (CV) 
(20  ng mL-1) 
RE (CV) 
 (200  ng mL-1) 
ME (CV)  
(200  ng mL-1) 
Therapeutic range/ 
 Legal threshold 
(ng mL-1) 
 
6-MAM 5 1 90% (6%) 5% (7%) 57% (19%) -5% (3%) -  
Aminoclonazepam 10 10 72% (10%) -27% (4%)  41% (10%) -19% (5%) -  
Amitryptiline 1 < 1 94% (10%)  208% (23%) 46% (20%) 100% (12%) 50-300  
Amphetamine 10 1 49% (5%) -5% (7%) 25% (5%) 48% (4%) 15  
Benzoylecgonine 1 < 1 36% (5%) -16% (5%) 24% (6%) -8% (2%) -  
Benzylpiperazine 1 < 1 88% (5%) -3% (8%) 38% (27%) -16% (5%) -  
Butylone 1 < 1 65% (5%) -4% (7%) 30% (24%) -5% (5%) -  
Carbamezapine 1 < 1 89% (4%) -18% (4%) 55% (10%) -10% (3%) 200-800  
Citalopram 1 < 1 110% (10%) 31% (18%) 61% (17%) -14% (11%) 50-110  
Cocaine 1 < 1 121% (5%) 29% (9%) 60% (11%) -2% (7%) 15  
Codeine 5 1 72% (6%) -5% (5%) 52% (8%) -3% (2%) 30-250  
Diazepam 1 < 1 88% (8%) -20% (7%) 47% (7%) -16% (2%) 100-2000  
Fluoxetine 1 < 1 113% (19%) 319% (28%) 71% (19%) 178% (10%) 120-500  
Gabapentin 20 5 57% (15%) -35% (42%) 39% (6%) -22% (21%) 50-600  
Haloperidol 1 < 1 106% (19%) 170% (19%) 57% (19%) 114% (11%) 5-17  
Hydroxymidazolam 1 < 1 90% (8%) -28% (4%) 49% (15%) -23% (4%) -  
Ketamine 5 1 71% (2%) 6% (7%) 34% (13%) -3% (3%) 1000-6000  
MDMA 1 < 1 68% (3%) -9% (6%) 33% (34%) -9% (5%) 15  
Methadone 1 < 1 99% (11%) 21% (21%) 48% (21%) -15% (9%) 100-500  
Methamphetamine 1 < 1 49% (5%) -10% (8%) 22% (6%) -13% (4%) 15  
Methedrone 1 < 1 68% (3%) -9% (6%) 33% (34%) -9% (5%) -  
Methylone 1 < 1 58% (4%) -17% (9%) 25% (31%) -17% (4%) -  
Mianserin 1 < 1 84% (6%) 122% (16%) 37% (17%) 36% (9%) 15-70  
Midazolam 1 < 1 73% (7%) -18% (3%) 51% (9%) -11% (3%) 40-100  
Morphine 10 5 56% (5%) -10% (4%) 19% (41%) 38% (9%) 15 (free form)  
Quetiapine 1 < 1 98% (3%) 85% (7%) 57% (13%) 31% (3%) 100-500  
Risperidone 1 < 1 107% (11%) 111% (16%) 57% (19%) 30% (10%) 6-20  
THC-COOH 10 5 49% (6%) -53% (6%) 28% (16%)  -41% (6%) -  
Trimipramine 5 1 89% (14%) 166% (26%) 43% (17%) 66% (15%) 10-30  
Zolpidem 1 < 1 90% (7%) 32% (4%) 51% (7%) 9% (4%) 80-150  
Table 1: List of the 30 substances used for the method evaluation with their respective limits of 
identification (LOIs), limits of detection (LODs) and therapeutic ranges or legal thresholds. 
Matrix effect (ME) and recovery (RE) were evaluated at two concentration levels (20 and 200 ng 
mL-1) on thoses substances involving a representative panel of the classes of the molecules of 
interest. 
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Figures: 416 
Figure 1: 104 real cases have been analyzed by the developed method and two other routine methods. The Venn 417 
diagram represents the percentage of identification performed by each method (A). The results were confirmed 418 
by quantitative analysis of the substances targeted by all 3 methods. The percentage of identification not 419 
performed by the routine approaches is represented depending on the concentration (B). 420 
421 
422 
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Figure 2: The case apparition percentage in the 104 real cases is represented by bar charts. 423 
 424 
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Highlights:  
• First study on the application of dried blood spot (DBS) microsampling hyphenated 
with LC and Orbitrap technology for clinical and forensic toxicology screening 
• Minimal blood volume requirement for powerful screening anf identification using 
high resolution MS. 
• Validation of the developed method according to guidelines for qualitative approaches 
and assessment using 104 real cases analysed by reference approaches. 
• Great relevance for practice in clinical and forensic toxicology opening new 
opportunities towards friendly sampling process in non-medical environments. 
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